← Patent-cliff monitor small molecule QELBREE VILOXAZINE HYDROCHLORIDE
Loss of exclusivity April 2035 latest FDA-listed patent expiry
Drug detail Brand name QELBREE Active ingredient VILOXAZINE HYDROCHLORIDE Strength EQ 200MG BASE Dosage form CAPSULE, EXTENDED RELEASE Route ORAL Modality Small molecule FDA approval April 2021 Marketing status RX
Listed patents Patent Expires Type 9662338 April 2035 product 9603853 February 2033 use U-727 9358204 February 2033 product 12121523 September 2029 use U-727 11458143 September 2029 use U-727 11324753 September 2029 use U-727
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.